JAK3 and mature T-cell and NK-cell non-Hodgkin lymphoma: Whether combining azacytidine with JAK3 inhibitors improves tolerability and efficacy in PTCL remains to be seen, although pSTAT3 targeting by combined inhibition of JAK3 and DNMT seems promising.